Business Context and Reporting Period
Company: Microbot Medical Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 14, 2025
Principal Event: Entry into a Material Definitive Agreement (Inducement Transaction) involving the exercise of existing Preferred Investment Options (PIOs) and the issuance of new Series J PIOs.
Key Financial Metrics and Transaction Details
- Gross Proceeds (First Closing): Approximately $25.2 million received on September 16, 2025, from the exercise of 12,064,627 shares of Common Stock.
- Expected Gross Proceeds (Second Closing): Approximately $4.0 million expected by October 15, 2025, from the exercise of 1,924,488 shares.
- Total Transaction Volume: Aggregate of 13,989,115 shares of Common Stock purchased via existing PIOs (Series F, G, H, I) at exercise prices ranging from $1.50 to $2.13 per share.
- New Securities Issued: New Series J PIOs issued to purchase up to 13,989,115 shares at an exercise price of $4.50 per share.
- Placement Agent Fees: H.C. Wainwright & Co., LLC to receive a 7.0% cash fee plus a 1.0% management fee on gross proceeds, plus specific PIOs and expense reimbursements.
- Use of Proceeds: Development and commercialization of the LIBERTY Robotic System, regulatory activities, potential acquisitions, and working capital.
Material Changes and Transaction Structure
The filing details a two-closing inducement transaction designed to raise capital while providing investors with new upside potential:
- First Closing (Completed): Occurred on September 16, 2025. Holders exercised existing options for cash and received new Series J PIOs for an equivalent number of shares.
- Second Closing (Pending): Expected by October 15, 2025. A specific holder will exercise remaining options at $2.10 per share and receive corresponding new PIOs.
- Terms of New PIOs: Exercisable six months after issuance; expire two years thereafter. Exercise price is fixed at $4.50 per share.
- Restrictions: The Company agreed to a 90-day lock-up on issuing new Common Stock or equivalents and a six-month restriction on entering variable rate transactions.
Outlook, Risks, and Contingencies
- Liquidity Risk: There is no established trading market for the new Series J PIOs, and the Company does not expect one to develop, resulting in extremely limited liquidity for these instruments.
- Registration Requirements: The Company must file a resale registration statement (Form S-3 or S-1) within 30 days and seek effectiveness within 60 days to allow holders to resell shares upon exercise.
- Ownership Caps: Holders are restricted from exercising options if it would result in ownership exceeding 4.99% (or 9.99% with notice) of outstanding Common Stock.
- Future Compensation: Upon future cash exercises of the New PIOs, the Company must pay Wainwright an additional 7% cash fee and issue 5% of the underlying shares as new PIOs.
Investor Verification Checklist
- Verify the final closing date and actual proceeds received for the Second Closing (expected by October 15, 2025).
- Confirm the effectiveness of the Resale Registration Statement (Form S-3 or S-1) required within 60 days of the Letter Agreement.
- Monitor the Company's cash burn rate relative to the $29.2 million total expected gross proceeds to assess runway for the LIBERTY Robotic System development.
- Review the dilution impact of the 13,989,115 new Series J PIOs and the additional Wainwright PIOs issued as compensation.
- Check for any subsequent filings regarding the 90-day restriction on new equity issuances.